CLAIMS

1. *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited at the *Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH* -DSMZ, with deposit number DSM 33960.

2. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, according to claim 1, for use as a medicament.

3. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, according to claim 1 or 2, for use in the prevention and/or treatment of diseases related to dysbiosis of the microbiota of the urogenital tract, preferably the female urogenital tract.

4. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to claim 3 , wherein said dysbiosis refers to dysbiosis of the vaginal microbiota.

5. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to claim 3 or 4, wherein said diseases related to dysbiosis of the microbiota of the female urogenital tract are selected from the group comprising or alternatively consisting of vaginal infections, urogenital tract infections, vaginal inflammation, inflammation of the urogenital tract, bacterial vaginosis (BV) and recurrences thereof, vulvovaginal candidiasis (VVC), sexually transmitted bacterial infections preferably carried by *Chlamydia trachomatis, Neisseria gonorrhoeae* and *Trichomonas vaginalis*, mixed dysbiosis, group B *Streptococci* (GBS) infections.

6. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to claim 5, wherein said urogenital tract infections are selected from infections/inflammations due to one or more microorganisms such as *Gardnerella vaginalis*, *Escherichia coli*, *Staphylococcus aureus, Candida* spp*, Candida albicans*, *Candida krusei*, *Candida glabrata*, Candida *parapsilosis, Candida tropicalis, Listeria monocytogenes, Pseudomonas aeruginosa, Pseudomonas monteilii,* and *Streptococcus agalactiae* and/or combinations thereof.

7. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to any one of claims 2 to 6, wherein said bacterial strain is to be administered orally.

8. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to any one of claims 2 to 7, wherein said bacterial strain is in lyophilized form.

9. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to any one of claims 2 to 8, wherein said bacterial strain is to be administered in combination with one or more antimicrobial agents.

10. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to claim 9, wherein said one or more antimicrobial agents are selected from metronidazole, clotrimazole, boric acid, fluconazole and mixtures thereof.

11. The *Lacticaseibacillus rhamnosus* CA15 bacterial strain, deposited under DSM deposit number 33960, for use according to any one of claims 2 to 9, wherein said bacterial strain is to be administered in capsule form.